Skip to content

Evaluation of gynecological and dermatological acceptability of health products using the product at home

Evaluation of gynecological and dermatological acceptability of health products under normal conditions of use_Ave02.2021

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-3q8syh4
Enrollment
Unknown
Registered
2021-12-08
Start date
2022-03-21
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Interventions

Sponsors

Ipclin Instituto de Pesquisa Clínica Integrada Ltda
Lead Sponsor
Avenca Indústria Cosmética Eireli -EPP
Collaborator

Eligibility

Age
18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Women; age: 18 to 59 years; phototype: I to IV; whole skin of the region; occasional user of category products

Exclusion criteria

Exclusion criteria: Skin marks in the experimental area that interfere with the assessment of possible reactions; Pregnant or lactating women; Participants with a history of allergy to the material used in the study; Atopy history; Use of vaginal cream; Participants with a history of allergy to products from the tested category; Recent gynecological surgeries; Discharges; Immunodeficiency patients; Kidney, cardiac or liver transplants; Active skin conditions that may interfere with the study (vitiligo, psoriasis, lupus, atopic dermatitis); Topical use with corticosteroids in the experimental area up to 8 days before the start of the study.; Any condition not mentioned above that, in the investigator's opinion, could compromise the study evaluation

Design outcomes

Primary

MeasureTime frame
It is expected to verify the acceptability of the investigational product, an intimate lubricant, in the studied population, after using the products in real conditions of use, through dermatological and gynecological medical evaluation of clinical signs and feelings of discomfort, based on the finding of that none of the participants presented discomfort or clinical signs, considering the product as gynecologically and dermatologically tested.

Secondary

MeasureTime frame
It is expected to guarantee the safety of the product, an intimate lubricant, to the end users, based on the observation that none of the participants presented discomfort or clinical signs.

Countries

Brazil

Contacts

Public ContactCassiano Escudeiro
cassiano@ipclin.com.br+55 011 4087-0092

Outcome results

None listed

Source: REBEC (via WHO ICTRP)